Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics stockholders approve ESPP share increase at June 25 annual meeting

Neutral Impact 2 of 5 shareholder Written later

At its June 25, 2026 Annual Meeting, Aligos Therapeutics stockholders approved an amendment to the 2020 Employee Stock Purchase Plan that reserves 500,000 additional shares and removes the plan's automatic annual share-reserve increases through 2030. Stockholders also elected two Class III directors, ratified Ernst & Young LLP as auditor for 2026, and backed an annual frequency for future advisory pay votes.

Key points

  • ESPP amendment reserves 500,000 additional shares and eliminates the evergreen provision, so the reserve will be fixed with no further automatic increases.
  • Proposal 3 (ESPP amendment) received 2,161,966 votes for, 17,797 against, 1,108 abstentions and 1,613,003 broker non-votes.
  • Bridget Martell and Carole Nuechterlein were elected as Class III directors, with 2,092,164 and 2,086,481 votes for, respectively.
  • The Company will hold advisory say-on-pay votes annually, following 2,077,884 stockholder votes for a one-year frequency.

The filing

CompanyAligos Therapeutics, Inc. (ALGS)
Form8-K, current report
Filed with the SECJun 26, 2026, 4:02 PM ET
Accession number0001193125-26-285426

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.